Stemline Therapeutics (NASDAQ:STML) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday.
A number of other research firms have also commented on STML. Zacks Investment Research upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 22nd. HC Wainwright restated a “buy” rating on shares of Stemline Therapeutics in a research note on Monday, June 18th. ValuEngine lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 16th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research note on Friday, June 15th. Finally, Roth Capital started coverage on shares of Stemline Therapeutics in a research note on Tuesday, June 12th. They issued a “buy” rating and a $30.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Stemline Therapeutics currently has an average rating of “Buy” and an average target price of $30.00.
Shares of NASDAQ:STML opened at $15.15 on Tuesday. Stemline Therapeutics has a 12 month low of $7.30 and a 12 month high of $20.55. The firm has a market cap of $452.60 million, a P/E ratio of -5.15 and a beta of 0.05.
Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.02). The company had revenue of $0.50 million for the quarter. analysts predict that Stemline Therapeutics will post -2.73 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. BlueMountain Capital Management LLC acquired a new position in Stemline Therapeutics in the second quarter valued at $137,000. State Board of Administration of Florida Retirement System acquired a new position in Stemline Therapeutics in the second quarter valued at $166,000. Two Sigma Investments LP acquired a new position in Stemline Therapeutics in the fourth quarter valued at $170,000. MetLife Investment Advisors LLC acquired a new position in Stemline Therapeutics in the fourth quarter valued at $186,000. Finally, Sofinnova Ventures Inc purchased a new stake in shares of Stemline Therapeutics in the first quarter valued at about $193,000. Institutional investors own 67.22% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Featured Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.